This Author published in this journals
All Journal Scientific Nexus
Anisa Salwa Razika
Department of Pharmacy, Faculty of Science, Institut Teknologi Sumatera, South Lampung 35365, Lampung, Indonesia

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

Sanggenon C from Morus alba as a promising Bcl-2 inhibitor: a molecular docking study targeting apoptosis in lung cancer Adelweis Putrinda; Anisa Salwa Razika; Dewi Nadia Luthfi; Nabila Tri Elmerillia; Nabilla Intan Safira; Anjar Hermadi Saputro; Winni Nur Auli
Scientific Nexus Vol. 2 No. 2 (2026): Scientific Nexus
Publisher : Fakultas Sains Institut Teknologi Sumatera

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35472/scinexus.2721

Abstract

Bcl-2 overexpression is a key driver of apoptosis evasion and chemoresistance in lung cancer. Morus alba L. harbors bioactive phytochemicals with reported anticancer properties, yet their binding potential against Bcl-2 remains computationally unevaluated. This study aims to assess the binding affinity and interaction profiles of five M. alba-derived compounds—sanggenon C, morusin, albanol B, rutin, and kuwanon C—against Bcl-2 using molecular docking. Molecular docking was performed using AutoDockTools® (v1.5.7) with the Bcl-2 crystal structure (PDB ID: 6O0K) and venetoclax as the reference ligand. Binding free energy (ΔG), binding site similarity (%BSS), and hydrogen bond interactions were analyzed. Redocking yielded an RMSD of 1.41 Å, confirming protocol validity. Sanggenon C exhibited the most favorable binding profile (ΔG = −8.46 kcal/mol; %BSS = 81.25%), sharing 13 of 16 key residues with venetoclax, including Phe112, Val156, Met115, Phe153, Arg146, and Gly145, with three hydrogen bonds predominantly within the optimal range. These findings establish a computational basis for prioritizing sanggenon C as a Bcl-2 inhibitor lead from M. alba, warranting further validation through ADMET profiling, molecular dynamics simulation, and in vitro cytotoxicity and apoptosis assays in lung cancer cell models.